Short Interest in Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) Increases By 689.6%

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) saw a significant increase in short interest in the month of May. As of May 31st, there was short interest totalling 586,700 shares, an increase of 689.6% from the May 15th total of 74,300 shares. Based on an average daily trading volume, of 2,290,000 shares, the days-to-cover ratio is currently 0.3 days.

Sonoma Pharmaceuticals Trading Down 3.0 %

SNOA traded down $0.01 on Thursday, reaching $0.18. The stock had a trading volume of 1,249,650 shares, compared to its average volume of 2,281,945. The business’s 50-day moving average price is $0.18 and its two-hundred day moving average price is $0.17. Sonoma Pharmaceuticals has a 12-month low of $0.12 and a 12-month high of $1.38. The company has a market cap of $2.86 million, a P/E ratio of -0.19 and a beta of 1.37.

Sonoma Pharmaceuticals Company Profile

Sonoma Pharmaceuticals, Inc, develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis.